Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

PURPOSE: Talazoparib has demonstrated efficacy in patients with BRCA-positive metastatic breast cancer. This study evaluated the pathologic response of talazoparib alone for 6 months in patients with a known germline BRCA pathogenic variant (gBRCA-positive) and operable breast cancer. METHODS: Eligi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Litton, Jennifer K., Scoggins, Marion E., Hess, Kenneth R., Adrada, Beatriz E., Murthy, Rashmi K., Damodaran, Senthil, DeSnyder, Sarah M., Brewster, Abenaa M., Barcenas, Carlos H., Valero, Vicente, Whitman, Gary J., Schwartz-Gomez, Jill, Mittendorf, Elizabeth A., Thompson, Alastair M., Helgason, Thorunn, Ibrahim, Nuhad, Piwnica-Worms, Helen, Moulder, Stacy L., Arun, Banu K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
RAPID COMMUNICATIONS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7351336/
https://ncbi.nlm.nih.gov/pubmed/31461380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01304
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados